Adverse Reaction of HIPEC Combined with Intravenous Chemotherapy on Ovarian Cancer Patients

Abstract

Objective To evaluate adverse reactions of the hyperthermic intraperitoneal chemotherapy (HIPEC) combined with intravenous chemotherapy in the treatment of ovarian cancer(OC) after the cytoreductive surgery (CRS), and to analyse the effect of adverse reactions on the survival time of patients. Methods We selected 163 patients with ovarian cancer. All patients got CRS for OC, and then were divided into two groups according to the different treatment modes: observation group (n=47, HIPEC in combination of intravenous chemotherapy) and control group (n=116, intravenous chemotherapy). The adverse reactions of the two groups were observed. All patients were followed up after operation. Results The incidence of hypoproteinemia in the observation group was higher than that in the control group, while the incidence of leukopenia, thrombocytopenia, abdominal distention and abdominal pain were lower than those in the control group (P 2 cycles of HIPEC were increased (P < 0.05). There was no significant difference in overall survival rate between the two groups. The survival of patients without anemia or mild anemia in the observation group was better than that of patients with severe anemia (P < 0.05). The occurrence of other adverse reactions had no significant effect on the overall survival rate of the patients. Conclusion HIPEC combined with intravenous chemotherapy after CRS would not increase adverse reactions, especially severe adverse reactions in OC patients, but there is a high incidence of hypoproteinemia.

Keywords

• ovarian cancer
• hyperthermic intraperitoneal chemotherapy
• intravenous chemotherapy
• adverse reaction